MCP4 como biomarcador de diagnóstico en Esclerosis Sistémica

El presente proyecto de investigación tiene como objetivo evaluar la proteína MCP4 como biomarcador candidato para el diagnóstico de la Esclerosis Sistémica, una enfermedad autoinmune que implica vasculopatía, respuesta inmune desregulada y fibrosis. Esta enfermedad se presenta frecuentemente en las...

Full description

Autores:
Mayorga Jimenez, Juana Camila
Tipo de recurso:
Trabajo de grado de pregrado
Fecha de publicación:
2024
Institución:
Colegio Mayor de Cundinamarca
Repositorio:
Repositorio Colegio Mayor de Cundinamarca
Idioma:
spa
OAI Identifier:
oai:repositorio.unicolmayor.edu.co:unicolmayor/7033
Acceso en línea:
https://repositorio.unicolmayor.edu.co/handle/unicolmayor/7033
Palabra clave:
Autoinmunidad
Esclerosis Sistémica
Respuesta inmune
Proteína
Biomarcador
Concentración
Fisiopatología
Diagnostico
Rights
closedAccess
License
Derechos Reservados - Universidad Colegio Mayor de Cundinamarca, 2024
id UCOLMAYOR2_1a8d439a7aa4e300cce36950c8467225
oai_identifier_str oai:repositorio.unicolmayor.edu.co:unicolmayor/7033
network_acronym_str UCOLMAYOR2
network_name_str Repositorio Colegio Mayor de Cundinamarca
repository_id_str
dc.title.spa.fl_str_mv MCP4 como biomarcador de diagnóstico en Esclerosis Sistémica
title MCP4 como biomarcador de diagnóstico en Esclerosis Sistémica
spellingShingle MCP4 como biomarcador de diagnóstico en Esclerosis Sistémica
Autoinmunidad
Esclerosis Sistémica
Respuesta inmune
Proteína
Biomarcador
Concentración
Fisiopatología
Diagnostico
title_short MCP4 como biomarcador de diagnóstico en Esclerosis Sistémica
title_full MCP4 como biomarcador de diagnóstico en Esclerosis Sistémica
title_fullStr MCP4 como biomarcador de diagnóstico en Esclerosis Sistémica
title_full_unstemmed MCP4 como biomarcador de diagnóstico en Esclerosis Sistémica
title_sort MCP4 como biomarcador de diagnóstico en Esclerosis Sistémica
dc.creator.fl_str_mv Mayorga Jimenez, Juana Camila
dc.contributor.advisor.none.fl_str_mv Ramirez Santana, Carolina
Cruz Baquero, Claudia
dc.contributor.author.none.fl_str_mv Mayorga Jimenez, Juana Camila
dc.subject.proposal.spa.fl_str_mv Autoinmunidad
Esclerosis Sistémica
Respuesta inmune
Proteína
Biomarcador
Concentración
Fisiopatología
Diagnostico
topic Autoinmunidad
Esclerosis Sistémica
Respuesta inmune
Proteína
Biomarcador
Concentración
Fisiopatología
Diagnostico
description El presente proyecto de investigación tiene como objetivo evaluar la proteína MCP4 como biomarcador candidato para el diagnóstico de la Esclerosis Sistémica, una enfermedad autoinmune que implica vasculopatía, respuesta inmune desregulada y fibrosis. Esta enfermedad se presenta frecuentemente en las mujeres, en una edad promedio de 45 años. A pesar de tener una prevalencia baja, su mortalidad es alta y ha sido clasificada en Colombia como una enfermedad huérfana, debido a su heterogeneidad en su presentación clínica es de difícil tratamiento y diagnóstico. La detección temprana de esta enfermedad es fundamental para un manejo clínico efectivo, es por ello que investigadores están en busca de un biomarcador que permita un diagnóstico temprano, mejorando la calidad de vida del paciente. Se propone la proteína MCP4 como biomarcador de diagnóstico para Esclerosis Sistémica basado en su implicación en la fisiopatología de la enfermedad. Para su estudio, se llevará a cabo la recolección de muestras de suero sanguíneo de pacientes diagnosticados con Esclerosis MCP4 COMO BIOMARCADOR DE ESCLEROSIS SISTEMICA Sistémica y un grupo de individuos sanos como controles. Se analizarán los niveles séricos de la proteína MCP4 y se evaluará su correlación con parámetros clínicos pertinentes. Los resultados de esta investigación pretenden contribuir al diagnóstico temprano de la esclerosis sistémica y a una comprensión de la fisiopatología de este trastorno.
publishDate 2024
dc.date.accessioned.none.fl_str_mv 2024-08-07T00:15:34Z
dc.date.available.none.fl_str_mv 2024-08-07T00:15:34Z
dc.date.issued.none.fl_str_mv 2024
dc.type.spa.fl_str_mv Trabajo de grado - Pregrado
dc.type.coar.spa.fl_str_mv http://purl.org/coar/resource_type/c_7a1f
dc.type.coarversion.spa.fl_str_mv http://purl.org/coar/version/c_970fb48d4fbd8a85
dc.type.content.spa.fl_str_mv Text
dc.type.driver.spa.fl_str_mv info:eu-repo/semantics/bachelorThesis
dc.type.redcol.spa.fl_str_mv https://purl.org/redcol/resource_type/TP
dc.type.version.spa.fl_str_mv info:eu-repo/semantics/publishedVersion
format http://purl.org/coar/resource_type/c_7a1f
status_str publishedVersion
dc.identifier.uri.none.fl_str_mv https://repositorio.unicolmayor.edu.co/handle/unicolmayor/7033
url https://repositorio.unicolmayor.edu.co/handle/unicolmayor/7033
dc.language.iso.spa.fl_str_mv spa
language spa
dc.relation.references.spa.fl_str_mv Jorge Mario Palmezano-Díaz, Claudia Lucía Figueroa-Pineda, Reynaldo Mauricio Rodríguez-Amaya, Lisette Katherine Plazas-Rey. Prevalence and characterization of autoimmune diseases in patients older than 13 years in a hospital of Colombia. Medicina interna de Mexico. 2018;34(4).
Abul K. Abbas AHLSP. Mecanismos de autoinmunidad . In: Inmunología celular y molecular. 9th ed. 2018.
Nicole JA, Iván GA. Inmunopatogenia de las enfermedades autoinmunes. Revista Médica Clínica Las Condes. 2012 Jul;23(4):464–72.
Lerner A, Jeremias P, Matthias T. The World Incidence and Prevalence of Autoimmune Diseases is Increasing. International Journal of Celiac Disease. 2016 May 5;3(4):151–5.
Londoño J, Peláez Ballestas I, Cuervo F, Angarita I, Giraldo R, Rueda JC, et al. Prevalencia de la enfermedad reumática en Colombia, según estrategia COPCORD- Asociación Colombiana de Reumatología. Estudio de prevalencia de enfermedad reumática en población colombiana mayor de 18 años. Revista Colombiana de Reumatología. 2018 Oct;25(4):245–56.
Rosendahl A, Schönborn K, Krieg T. Pathophysiology of systemic sclerosis (scleroderma). Kaohsiung J Med Sci. 2022 Mar 2;38(3):187–95.
J. J. Alegre Sancho EBCICVNFLJICJARI. Esclerosis sistemica . In: Enfermedades reumáticas: Actualización SVR. Valencia: Hospital Universitario Dr. Peset;
Jerjen R, Nikpour M, Krieg T, Denton CP, Saracino AM. Systemic sclerosis in adults. Part I: Clinical features and pathogenesis. J Am Acad Dermatol. 2022 Nov;87(5):937– 54.
Bobeica C, Niculet E, Halip A, Gheuca-Solovastru L, Draganescu M, Popescu I, et al. Predictive value of immunological markers in systemic sclerosis. Exp Ther Med. 2021 Jul 14;22(3):994.
Furue M, Mitoma C, Mitoma H, Tsuji G, Chiba T, Nakahara T, et al. Pathogenesis of systemic sclerosis—current concept and emerging treatments. Immunol Res. 2017 Aug 9;65(4):790–7.
Sandra S. Arango V. Biomarkers for the evaluation of human health risks. Revista Facultad Nacional de Salud Pública. 2012;
Coffey C, Radwan Y, Sandhu A, Crowson CS, Bauer P, Matteson E, et al. POS0838 EPIDEMIOLOGY AND TRENDS IN SURVIVAL OF SYSTEMIC SCLEROSIS IN OLMSTED COUNTY: A POPULATION-BASED STUDY (1980-2018). Ann Rheum Dis. 2021 Jun 19;80(Suppl 1):673.1-673.
MANNO RL, WIGLEY FM, GELBER AC, HUMMERS LK. Late-age Onset Systemic Sclerosis. J Rheumatol. 2011 Jul;38(7):1317–25.
Bergamasco A, Hartmann N, Wallace L, Verpillat P. <p>Epidemiology of systemic sclerosis and systemic sclerosis-associated interstitial lung disease</p>. Clin Epidemiol. 2019 Apr;Volume 11:257–73.
The Lancet. Reducing the cost of rare disease drugs. The Lancet. 2015 Feb;385(9970):746.
MinSalud. Resolución 023 de 2023- Enfermedades huerfanas. Ministerio de Salud y Protección Social, 023 Colombia; Jan 4, 2023.
Ministerio de salud. Enfermedades huerfanas. 2023 Jan.
Castro S V, Jimenez SA. Biomarkers in systemic sclerosis. Biomark Med. 2010 Feb;4(1):133–47.
Arron JR. Biomarkers in systemic sclerosis: mechanistic insights into pathogenesis and treatment. Curr Opin Rheumatol. 2021 Nov;33(6):480–5.
Hasegawa M, Sato S, Echigo T, Hamaguchi Y, Yasui M, Takehara K. Up regulated expression of fractalkine/CX3CL1 and CX 3CR1 in patients with systemic sclerosis. Ann Rheum Dis. 2005;64(1).
O’Brien JC, Rainwater YB, Malviya N, Cyrus N, Auer-Hackenberg L, Hynan LS, et al. Transcriptional and Cytokine Profiles Identify CXCL9 as a Biomarker of Disease Activity in Morphea. Journal of Investigative Dermatology. 2017 Aug;137(8):1663– 70.
Li L, Dai F, Wang L, Sun Y, Mei L, Ran Y, et al. CCL13 and human diseases. Front Immunol. 2023 Apr 19;14.
LAMKHIOUED B, GARCIA-ZEPEDA EA, ABI-YOUNES S, NAKAMURA H, JEDRZKIEWICZ S, WAGNER L, et al. Monocyte Chemoattractant Protein (MCP)-4 Expression in the Airways of Patients with Asthma. Am J Respir Crit Care Med. 2000 Aug 1;162(2):723–32.
Iwamoto T, Okamoto H, Iikuni N, Takeuchi M, Toyama Y, Tomatsu T, et al. Monocyte chemoattractant protein-4 (MCP-4)/CCL13 is highly expressed in cartilage from patients with rheumatoid arthritis. Rheumatology (Oxford). 2006 Apr;45(4):421– 4.
Truchetet ME, Brembilla NC, Chizzolini C. Current Concepts on the Pathogenesis of Systemic Sclerosis. Clin Rev Allergy Immunol. 2021 Sep 6;64(3):262–83.
Unidad de enfermedades autoinmunes: experiencia de un centro. Revista Uruguaya de Medicina Interna. 2020 Oct 10;05(03).
Arnett FC. HLA and Autoimmunity in Scleroderma (Systemic Sclerosis). Int Rev Immunol. 1995 Jan 10;12(2–4):107–28.
Diot E. Systemic sclerosis and occupational risk factors: a case-control study. Occup Environ Med. 2002 Aug 1;59(8):545–9.
Garabrant DH. Scleroderma and Solvent Exposure among Women. Am J Epidemiol. 2003 Mar 15;157(6):493–500.
Olink [Internet]. 2023. Proximity Extension Assay (PEA) technology.
Yanaba K, Yoshizaki A, Muroi E, Hara T, Ogawa F, Shimizu K, et al. CCL13 is a promising diagnostic marker for systemic sclerosis. British Journal of Dermatology. 2010;162(2).
Gabrielli A, Avvedimento E V, Krieg T. Scleroderma. N Engl J Med. 2009 May 7;360(19):1989–2003.
Mónica Ferrer Gracia, Laura María Cuadra Giménez, María de las Mercedes Díez Angulo, Alaitz Saiz Ferrer, María Sanmartín Xifré, Raúl Fernández Peñarroya. Esclerodermia: aspectos conceptuales, epidemiológicos, etiopatogénicos y clínicos. Artículo monográfico. Revista sanitaria de Investigación. 2021;
Rubio-Rivas M, Royo C, Simeón CP, Corbella X, Fonollosa V. Mortality and survival in systemic sclerosis: Systematic review and meta-analysis. Semin Arthritis Rheum. 2014 Oct;44(2):208–19.
Fernández-Ávila DG, Bernal-Macías S, Gutiérrez JM, Rincón DN, Rosselli D. Prevalence of systemic sclerosis in Colombia: Data from the National Health Registry 2012–2016. J Scleroderma Relat Disord. 2020 Jun 19;5(2):137–42.
Varga J, Trojanowska M, Kuwana M. Pathogenesis of systemic sclerosis: recent insights of molecular and cellular mechanisms and therapeutic opportunities. J Scleroderma Relat Disord. 2017 Sep 19;2(3):137–52.
Ruiz Gutiérrez L, Pérez Gómez A. Protocolo diagnóstico del fenómeno de Raynaud. Medicine - Programa de Formación Médica Continuada Acreditado. 2013;11(32):1997–2000.
Choi E, Henkin S. Raynaud’s phenomenon and related vasospastic disorders. Vascular Medicine. 2021 Feb 10;26(1):56–70.
Thulesius O. Methods for the evaluation of peripheral vascular function in the upper extremities. Acta Chir Scand Suppl. 1976;465:53–4.
Olga Lidia Vera Lastra. Esclerosis sistémica. Medicina Interna de México. 2006 May;22(3).
Shapiro SC, Wigley FM. Treating Raynaud phenomenon: Beyond staying warm. Cleve Clin J Med. 2017 Oct;84(10):797–804.
Consejo general de colegios oficiales de farmaceuticos. ESCLEROSIS SISTÉMICA (ESCLERODERMIA). Punto farmacologico . 2017;
Khanna D, Furst DE, Clements PJ, Allanore Y, Baron M, Czirjak L, et al. Standardization of the modified Rodnan skin score for use in clinical trials of systemic sclerosis. J Scleroderma Relat Disord. 2017;2(1):11–8.
Aspe Unanue L, González Hermosa MR, Gardeazabal García J. Esclerodermia (esclerosis sistémica). Piel. 2010 May;25(5):252–66.
Herrick AL, Assassi S, Denton CP. Skin involvement in early diffuse cutaneous systemic sclerosis: an unmet clinical need. Nat Rev Rheumatol. 2022 May 15;18(5):276–85.
Jiménez-Gallo D, Ossorio-García L, Linares-Barrios M. Calcinosis cutis y calcifilaxis. Actas Dermosifiliogr. 2015 Dec;106(10):785–94.
Wilkinson JM, Halland M. Esophageal Motility Disorders. Am Fam Physician. 2020 Sep 1;102(5):291–6.
Centros para el control y prevencion de enfermedades. Información sobre la telangiectasia hemorrágica hereditaria. 2013.
Janosik DL, Osborn TG, Moore TL, Shah DG, Kenney RG, Zuckner J. Heart disease in systemic sclerosis. Semin Arthritis Rheum. 1989 Dec;19(3):191–200.
Steen VD. Kidney involvement in systemic sclerosis. Presse Med. 2014 Oct;43(10):e305–14.
Lock G, Holstege A, Lang B, Schölmerich J. Gastrointestinal manifestations of progressive systemic sclerosis. Am J Gastroenterol. 1997 May;92(5):763–71.
Azarbani N, Javadzadeh A, Mohseni I, Jalali A, Andalib E, Poormoghim H. Association of Musculoskeletal and Radiological Features with Clinical and Serological Findings in Systemic Sclerosis: A Single-Centre Registry Study. Mediterr J Rheumatol. 2020;31(3):341.
Paloma García de la Peña Lefebvre. Esclerosis sistémica. Sociedad Española de Reumatología Pediátrica . 2020;173–85.
Sobolewski P, Maślińska M, Wieczorek M, Łagun Z, Malewska A, Roszkiewicz M, et al. Systemic sclerosis – multidisciplinary disease: clinical features and treatment. Rheumatology. 2019 Sep 24;57(4):221–33.
De Pieri A, Korman BD, Jüngel A, Wuertz‐Kozak K. Engineering Advanced In Vitro Models of Systemic Sclerosis for Drug Discovery and Development. Adv Biol. 2021 Apr 15;5(4).
Marie I, Gehanno JF. Environmental risk factors of systemic sclerosis. Semin Immunopathol. 2015 Sep 4;37(5):463–73.
Luo Y, Wang Y, Wang Q, Xiao R, Lu Q. Systemic sclerosis: Genetics and epigenetics. J Autoimmun. 2013 Mar;41:161–7.
Ouchene L, Muntyanu A, Lavoué J, Baron M, Litvinov I V., Netchiporouk E. Toward Understanding of Environmental Risk Factors in Systemic Sclerosis. J Cutan Med Surg. 2021 Mar 28;25(2):188–204.
DENTON CP, BICKERSTAFF MCM, SHIWEN X, CARULLI MT, HASKARD DO, DUBOIS RM, et al. SERIAL CIRCULATING ADHESION MOLECULE LEVELS REFLECT DISEASE SEVERITY IN SYSTEMIC SCLEROSIS. Rheumatology. 1995;34(11):1048–54.
Bagabir RA, Syed F, Rautemaa R, McGrouther DA, Paus R, Bayat A. Upregulation of Toll-Like Receptors (TLRs) 6, 7, and 8 in Keloid Scars. Journal of Investigative Dermatology. 2011 Oct;131(10):2128–30.
Bhattacharyya S, Varga J. Emerging Roles of Innate Immune Signaling and Toll-Like Receptors in Fibrosis and Systemic Sclerosis. Curr Rheumatol Rep. 2015 Jan 22;17(1):2.
Tan FK, Zhou X, Mayes MD, Gourh P, Guo X, Marcum C, et al. Signatures of differentially regulated interferon gene expression and vasculotrophism in the peripheral blood cells of systemic sclerosis patients. Rheumatology. 2006 Jun 1;45(6):694–702.
Assassi S, Mayes MD, Arnett FC, Gourh P, Agarwal SK, McNearney TA, et al. Systemic sclerosis and lupus: Points in an interferon-mediated continuum. Arthritis Rheum. 2010 Feb;62(2):589–98.
Saigusa R, Asano Y, Taniguchi T, Yamashita T, Ichimura Y, Takahashi T, et al. Multifaceted contribution of the TLR4-activated IRF5 transcription factor in systemic sclerosis. Proceedings of the National Academy of Sciences. 2015 Dec 8;112(49):15136–41.
Bossini-Castillo L, Martín JE, Díaz-Gallo LM, Rueda B, Martín J. Genética de la esclerodermia. Reumatol Clin. 2010 Sep;6:12–5.
Brkic Z, van Bon L, Cossu M, van Helden-Meeuwsen CG, Vonk MC, Knaapen H, et al. The interferon type I signature is present in systemic sclerosis before overt fibrosis and might contribute to its pathogenesis through high BAFF gene expression and high collagen synthesis. Ann Rheum Dis. 2016 Aug;75(8):1567–73.
Stifano G, Christmann RB. Macrophage Involvement in Systemic Sclerosis: Do We Need More Evidence? Curr Rheumatol Rep. 2016 Jan 23;18(1):2.
Zhang Y, McCormick LL, Desai SR, Wu C, Gilliam AC. Murine Sclerodermatous Graft-Versus-Host Disease, a Model for Human Scleroderma: Cutaneous Cytokines, Chemokines, and Immune Cell Activation. The Journal of Immunology. 2002 Mar 15;168(6):3088–98.
Lescoat A, Lecureur V, Roussel M, Sunnaram BL, Ballerie A, Coiffier G, et al. CD16- positive circulating monocytes and fibrotic manifestations of systemic sclerosis. Clin Rheumatol. 2017 Jul 14;36(7):1649–54.
Yamamoto T, Eckes B, Krieg T. High expression and autoinduction of monocyte chemoattractant protein-1 in scleroderma fibroblasts. Eur J Immunol. 2001 Oct;31(10):2936–41.
Chizzolini C, Boin F. The role of the acquired immune response in systemic sclerosis. Semin Immunopathol. 2015 Sep 8;37(5):519–28.
O’Reilly S, Hugle T, van Laar JM. T cells in systemic sclerosis: a reappraisal. Rheumatology. 2012 Sep 1;51(9):1540–9.
Brown M, O’Reilly S. The immunopathogenesis of fibrosis in systemic sclerosis. Clin Exp Immunol. 2019 Feb 18;195(3):310–21.
Kalogerou A. Early T cell activation in the skin from patients with systemic sclerosis. Ann Rheum Dis. 2005 Aug 1;64(8):1233–5.
Thoreau B, Chaigne B, Renaud A, Mouthon L. Pathophysiology of systemic sclerosis. Presse Med. 2021 Apr;50(1):104087.
Hua-Huy T, Dinh-Xuan AT. Cellular and molecular mechanisms in the pathophysiology of systemic sclerosis. Pathologie Biologie. 2015 Apr;63(2):61–8.
Asano Y. The Pathogenesis of Systemic Sclerosis: An Understanding Based on a Common Pathologic Cascade across Multiple Organs and Additional Organ-Specific Pathologies. J Clin Med. 2020 Aug 19;9(9):2687.
HASEGAWA M. B lymphocytes: Shedding new light on the pathogenesis of systemic sclerosis. J Dermatol. 2010 Jan 24;37(1):3–10.
Yoshizaki A. Pathogenic roles of B lymphocytes in systemic sclerosis. Immunol Lett. 2018 Mar;195:76–82.
Roberts AB, Sporn MB. Physiological Actions and Clinical Applications of Transforming Growth Factor-β (TGF-β). Growth Factors. 1993 Jan 11;8(1):1–9.
Boltjes A, van Wijk F. Human Dendritic Cell Functional Specialization in Steady- State and Inflammation. Front Immunol. 2014 Apr 1;5.
Audiger C, Rahman MJ, Yun TJ, Tarbell K V., Lesage S. The Importance of Dendritic Cells in Maintaining Immune Tolerance. The Journal of Immunology. 2017 Mar 15;198(6):2223–31.
Granot T, Senda T, Carpenter DJ, Matsuoka N, Weiner J, Gordon CL, et al. Dendritic Cells Display Subset and Tissue-Specific Maturation Dynamics over Human Life. Immunity. 2017 Mar;46(3):504–15.
Carvalheiro T, Zimmermann M, Radstake TRDJ, Marut W. Novel insights into dendritic cells in the pathogenesis of systemic sclerosis. Clin Exp Immunol. 2020 Jun 11;201(1):25–33.
Shima Y. Cytokines Involved in the Pathogenesis of SSc and Problems in the Development of Anti-Cytokine Therapy. Cells. 2021 May 4;10(5):1104.
Kikuchi K, Hartl CW, Smith EA, LeRoy EC, Trojanowska M. Direct demonstration of transcriptional activation of collagen gene expression in systemic sclerosis fibroblasts: Insensitivity to TGFβ1 stimulation. Biochem Biophys Res Commun. 1992 Aug;187(1):45–50.
Juhl P, Bondesen S, Hawkins CL, Karsdal MA, Bay-Jensen AC, Davies MJ, et al. Dermal fibroblasts have different extracellular matrix profiles induced by TGF-β, PDGF and IL-6 in a model for skin fibrosis. Sci Rep. 2020 Oct 14;10(1):17300.
Igarashi A, Nashiro K, Kikuchi K, Sato S, Ihn H, Grotendorst GR, et al. Significant Correlation Between Connective Tissue Growth Factor Gene Expression and Skin Sclerosis in Tissue Sections from Patients with Systemic Sclerosis. Journal of Investigative Dermatology. 1995 Aug;105(2):280–4.
Aspe Unanue L, González Hermosa MR, Gardeazabal García J. Esclerodermia (esclerosis sistémica). Piel. 2010 May;25(5):252–66.
Umehara H, Kumagai S, Ishida H, Suginoshita T, Maeda M, Imura H. Enhanced production of interleukin‐2 in patients with progressive systemic sclerosis. hyperactivity of cd4‐positive t cells? Arthritis Rheum. 1988 Mar 29;31(3):401–7.
Maria ATJ, Bourgier C, Martinaud C, Borie R, Rozier P, Rivière S, et al. De la fibrogenèse à la fibrose : mécanismes physiopathologiques et présentations cliniques. Rev Med Interne. 2020 May;41(5):325–9.
Pannu J, Trojanowska M. Recent advances in fibroblast signaling and biology in scleroderma. Curr Opin Rheumatol. 2004 Nov;16(6):739–45.
Adriana Acosta Gómez. El fibroblasto: su origen, estructura, funciones y heterogeneidad. Universitas Odonto. 2006;25(57):26–33.
Ornitz DM, Itoh N. The Fibroblast Growth Factor signaling pathway. WIREs Developmental Biology. 2015 May 13;4(3):215–66.
Denton CP, Black CM, Abraham DJ. Mechanisms and consequences of fibrosis in systemic sclerosis. Nat Clin Pract Rheumatol. 2006 Mar;2(3):134–44.
Damoiseaux J, Potjewijd J, Smeets RL, Bonroy C. Autoantibodies in the disease criteria for systemic sclerosis: The need for specification for optimal application. J Transl Autoimmun. 2022;5:100141.
Chen XH, Huang S, Kerr D. Biomarkers in clinical medicine. IARC Sci Publ. 2011;(163):303–22.
van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A, et al. 2013 Classification Criteria for Systemic Sclerosis: An American College of Rheumatology/European League Against Rheumatism Collaborative Initiative. Arthritis Rheum. 2013 Nov;65(11):2737–47.
Anna Bazsó, Emese Kiss. The Role of Biomarkers in the Pathogenesis, Clinical Manifestations, and Therapeutic Approach in Systemic Sclerosis. Preprints (Basel). 2023 Aug 8;
Domsic RT, Medsger TA. Autoantibodies and Their Role in Scleroderma Clinical Care. Curr Treatm Opt Rheumatol. 2016 Sep 14;2(3):239–51.
Cavazzana I, Vojinovic T, Airo’ P, Fredi M, Ceribelli A, Pedretti E, et al. Systemic Sclerosis-Specific Antibodies: Novel and Classical Biomarkers. Clin Rev Allergy Immunol. 2022 Jun 18;64(3):412–30.
Kowal-Bielecka O, Fransen J, Avouac J, Becker M, Kulak A, Allanore Y, et al. Update of EULAR recommendations for the treatment of systemic sclerosis. Ann Rheum Dis. 2017 Aug;76(8):1327–39.
Chen XH, Huang S, Kerr D. Biomarkers in clinical medicine. IARC Sci Publ. 2011;(163):303–22.
Chen XH, Huang S, Kerr D. Biomarkers in clinical medicine. IARC Sci Publ. 2011;(163):303–22.
Utsunomiya A, Oyama N, Hasegawa M. Potential Biomarkers in Systemic Sclerosis: A Literature Review and Update. J Clin Med. 2020 Oct 22;9(11):3388.
Utsunomiya A, Oyama N, Hasegawa M. Potential Biomarkers in Systemic Sclerosis: A Literature Review and Update. J Clin Med. 2020 Oct 22;9(11):3388.
Farmaki E, Chatzistamou I, Kiaris H. Human MCP Chemokine Cluster. In: Encyclopedia of Signaling Molecules. Cham: Springer International Publishing; 2018. p. 2482–9.
Barinka C, Prahl A, Lubkowski J. Structure of human monocyte chemoattractant protein 4 (MCP-4/CCL13). Acta Crystallogr D Biol Crystallogr. 2008 Mar 1;64(3):273–8.
Mendez-Enriquez E, García-Zepeda EA. The multiple faces of CCL13 in immunity and inflammation. Inflammopharmacology. 2013 Dec 12;21(6):397–406.
Garcia-Zepeda EA, Combadiere C, Rothenberg ME, Sarafi MN, Lavigne F, Hamid Q, et al. Human monocyte chemoattractant protein (MCP)-4 is a novel CC chemokine with activities on monocytes, eosinophils, and basophils induced in allergic and nonallergic inflammation that signals through the CC chemokine receptors (CCR)-2 and -3. J Immunol. 1996 Dec 15;157(12):5613–26.
Li L, Dai F, Wang L, Sun Y, Mei L, Ran Y, et al. CCL13 and human diseases. Front Immunol. 2023 Apr 19;14.
Barinka C, Prahl A, Lubkowski J. Structure of human monocyte chemoattractant protein 4 (MCP-4/CCL13). Acta Crystallogr D Biol Crystallogr. 2008 Mar 1;64(3):273–8.
Hein H, Schlüter C, Kulke R, Christophers E, Schröder JM, Bartels J. Genomic Organization, Sequence Analysis and Transcriptional Regulation of the Human MCP-4 Chemokine Gene (SCYA13) in Dermal Fibroblasts: A Comparison to Other Eosinophilic β-Chemokines. Biochem Biophys Res Commun. 1999 Feb;255(2):470–6.
Gambichler T, Yilmaz E, Höxtermann S, Kolios A, Moritz R, Bechara FG, et al. Serum CCL13 levels in patients with systemic sclerosis and controls. British Journal of Dermatology. 2011 Jul;165(1):216–8.
Petering H, Höchstetter R, Kimmig D, Smolarski R, Kapp A, Elsner J. Detection of MCP-4 in dermal fibroblasts and its activation of the respiratory burst in human eosinophils. J Immunol. 1998 Jan 15;160(2):555–8.
Li L, Dai F, Wang L, Sun Y, Mei L, Ran Y, et al. CCL13 and human diseases. Front Immunol. 2023 Apr 19;14.
Yanaba K, Yoshizaki A, Muroi E, Hara T, Ogawa F, Shimizu K, et al. CCL13 is a promising diagnostic marker for systemic sclerosis. British Journal of Dermatology. 2010;162(2).
Polania Maria Daniela, Higuera Maria. FRECUENCIA DE POLIAUTOINMUNIDAD EN ESCLEROSIS SISTÉMICA. Universidad del Rosario . 2020 Jun;
Prince HE. Biomarkers for diagnosing and monitoring autoimmune diseases. Biomarkers. 2005 Jan 20;10(sup1):44–9.
Vona R, Giovannetti A, Gambardella L, Malorni W, Pietraforte D, Straface E. Oxidative stress in the pathogenesis of systemic scleroderma: An overview. J Cell Mol Med. 2018 Jul 17;22(7):3308–14.
Minier T, Guiducci S, Bellando-Randone S, Bruni C, Lepri G, Czirják L, et al. Preliminary analysis of the very early diagnosis of systemic sclerosis (VEDOSS) EUSTAR multicentre study: evidence for puffy fingers as a pivotal sign for suspicion of systemic sclerosis. Ann Rheum Dis 2014;73:2087-93
dc.rights.spa.fl_str_mv Derechos Reservados - Universidad Colegio Mayor de Cundinamarca, 2024
dc.rights.uri.spa.fl_str_mv https://creativecommons.org/licenses/by-nc-nd/4.0/
dc.rights.accessrights.spa.fl_str_mv info:eu-repo/semantics/closedAccess
dc.rights.creativecommons.spa.fl_str_mv Atribución-NoComercial-SinDerivadas 4.0 Internacional (CC BY-NC-ND 4.0)
dc.rights.coar.spa.fl_str_mv http://purl.org/coar/access_right/c_14cb
rights_invalid_str_mv Derechos Reservados - Universidad Colegio Mayor de Cundinamarca, 2024
https://creativecommons.org/licenses/by-nc-nd/4.0/
Atribución-NoComercial-SinDerivadas 4.0 Internacional (CC BY-NC-ND 4.0)
http://purl.org/coar/access_right/c_14cb
eu_rights_str_mv closedAccess
dc.format.extent.spa.fl_str_mv 72p.
dc.format.mimetype.spa.fl_str_mv application/pdf
dc.publisher.spa.fl_str_mv Universidad Colegio Mayor de Cundinamarca
dc.publisher.faculty.spa.fl_str_mv Facultad de Ciencias de la Salud
dc.publisher.program.spa.fl_str_mv Bacteriología y Laboratorio Clínico
institution Colegio Mayor de Cundinamarca
bitstream.url.fl_str_mv https://repositorio.unicolmayor.edu.co/bitstream/unicolmayor/7033/12/MCP4%20COMO%20BIOMARCADOR%20DE%20DIAGNOSTICO%20EN%20ESCLEROSIS%20SISTEMICA%20FINAL-JUANA%20MAYORGA%20JIMENEZ%20%281%29.pdf
https://repositorio.unicolmayor.edu.co/bitstream/unicolmayor/7033/13/CARTA%20DERECHOS%20DE%20AUTOR%20IP%202024.docx%20%2824%29.pdf
https://repositorio.unicolmayor.edu.co/bitstream/unicolmayor/7033/14/FORMATO%20IDENTIFICACIO%cc%81N%20TRABAJO%20DE%20GRADO%20MCP4.pdf
https://repositorio.unicolmayor.edu.co/bitstream/unicolmayor/7033/5/license.txt
https://repositorio.unicolmayor.edu.co/bitstream/unicolmayor/7033/6/MCP4%20COMO%20BIOMARCADOR%20DE%20DIAGNOSTICO%20EN%20ESCLEROSIS%20SISTEMICA%20FINAL-JUANA%20MAYORGA%20JIMENEZ%20%281%29.pdf.txt
https://repositorio.unicolmayor.edu.co/bitstream/unicolmayor/7033/8/CARTA%20DERECHOS%20DE%20AUTOR%20IP%202024.docx%20%2824%29.pdf.txt
https://repositorio.unicolmayor.edu.co/bitstream/unicolmayor/7033/10/FORMATO%20IDENTIFICACIO%cc%81N%20TRABAJO%20DE%20GRADO%20MCP4.pdf.txt
https://repositorio.unicolmayor.edu.co/bitstream/unicolmayor/7033/7/MCP4%20COMO%20BIOMARCADOR%20DE%20DIAGNOSTICO%20EN%20ESCLEROSIS%20SISTEMICA%20FINAL-JUANA%20MAYORGA%20JIMENEZ%20%281%29.pdf.jpg
https://repositorio.unicolmayor.edu.co/bitstream/unicolmayor/7033/9/CARTA%20DERECHOS%20DE%20AUTOR%20IP%202024.docx%20%2824%29.pdf.jpg
https://repositorio.unicolmayor.edu.co/bitstream/unicolmayor/7033/11/FORMATO%20IDENTIFICACIO%cc%81N%20TRABAJO%20DE%20GRADO%20MCP4.pdf.jpg
bitstream.checksum.fl_str_mv df4cee61891ab5e546e1d4c0964c7824
f83fd50d83dd30eacd27e01cbff63b7d
a5ce708657c4d520aa3638c487781ffe
2f9959eaf5b71fae44bbf9ec84150c7a
c7abe868c5aa95ed142fff1059dbc553
38d869c455dd226c5a8e04ec55247d27
208f81372697180681b2bef13526b827
a27e8afbd597ec8aa618a3272c1dc48d
1045ac1f786e56ae8268b72cc7c03086
3eadd79cc8860550531870c88635ec68
bitstream.checksumAlgorithm.fl_str_mv MD5
MD5
MD5
MD5
MD5
MD5
MD5
MD5
MD5
MD5
repository.name.fl_str_mv Biblioteca Digital Unicolmayor
repository.mail.fl_str_mv repositorio@unicolmayor.edu.co
_version_ 1812210019220848640
spelling Ramirez Santana, Carolinafd15d7a4f0096138eefe7e432940bf39Cruz Baquero, Claudia6943c3629c446434eddb5e86d4e42758Mayorga Jimenez, Juana Camila85c49e7606bc8f130fe834917f6b16442024-08-07T00:15:34Z2024-08-07T00:15:34Z2024https://repositorio.unicolmayor.edu.co/handle/unicolmayor/7033El presente proyecto de investigación tiene como objetivo evaluar la proteína MCP4 como biomarcador candidato para el diagnóstico de la Esclerosis Sistémica, una enfermedad autoinmune que implica vasculopatía, respuesta inmune desregulada y fibrosis. Esta enfermedad se presenta frecuentemente en las mujeres, en una edad promedio de 45 años. A pesar de tener una prevalencia baja, su mortalidad es alta y ha sido clasificada en Colombia como una enfermedad huérfana, debido a su heterogeneidad en su presentación clínica es de difícil tratamiento y diagnóstico. La detección temprana de esta enfermedad es fundamental para un manejo clínico efectivo, es por ello que investigadores están en busca de un biomarcador que permita un diagnóstico temprano, mejorando la calidad de vida del paciente. Se propone la proteína MCP4 como biomarcador de diagnóstico para Esclerosis Sistémica basado en su implicación en la fisiopatología de la enfermedad. Para su estudio, se llevará a cabo la recolección de muestras de suero sanguíneo de pacientes diagnosticados con Esclerosis MCP4 COMO BIOMARCADOR DE ESCLEROSIS SISTEMICA Sistémica y un grupo de individuos sanos como controles. Se analizarán los niveles séricos de la proteína MCP4 y se evaluará su correlación con parámetros clínicos pertinentes. Los resultados de esta investigación pretenden contribuir al diagnóstico temprano de la esclerosis sistémica y a una comprensión de la fisiopatología de este trastorno.INDICE DE FIGURAS INDICE DE TABLAS RESUMEN INTRODUCCIÓN 1. ANTECEDENTES 2. MARCO REFERENCIAL 2.1 Esclerosis sistémica (ES) 2. 2 Epidemiología 2.3 Manifestaciones clínicas 2.3.1 Afectación microvascular 2. 4 Fisiopatología de la esclerosis sistémica 2.5 Factores ambientales, genéticos y epigéneticos 2.6 Vasculopatía 2.7 Respuesta inmune 2.7.1 Inmunidad innata 2.7. 2 Inmunidad adaptativa 2.8 Citoquinas implicadas en la Esclerosis Sistémica 2.9 Fibrosis 2.9.1 Pericitos y células musculares lisas 2.9.2 Fibroblastos 2.10 Criterios de clasificación 2.11 Evaluación de autoanticuerpos 2.12 Tratamiento 2.13 Biomarcadores 2.13.1 Biomarcadores séricos propuestos para Esclerosis Sistémica 2.14 Proteínas quimioatrayentes MCP Y MCP-4/CCL13 2.14.1 Estructura proteica de MCP4 2.14.2 MCP4 en el proceso de inflamación 2.14.3 MCP4 y enfermedades autoinmunes 2.14.4 MCP4 y ES 3. DISEÑO METODOLOGICO 3.1 Universo, población y muestras 3.2 Hipótesis, variables e indicadores 3.2.1 Hipótesis 3.2.2 Variables 3.2.3 Indicadores 3.3 Objetivos 3.4 Técnicas y procedimientos 3.4.1 Obtención de las muestras 3.4.2 Evaluación de la proteína MCP4 en suero 3.4.3 Análisis Estadístico 4. RESULTADOS 4.1 Estado sociodemográfico de pacientes con Esclerosis Sistémica 4.2 Estado clínico de pacientes con Esclerosis Sistémica 4.2.1 Comorbilidades 4.2.2 Poliautoinmunidad 4.2.3 Criterios ACR/EULAR 2013 4.2.4 Tipo de Esclerosis Sistémica según su extensión cutánea 4.3 Identificación de la proteína MCP4 en pacientes con Esclerosis Sistémica 4.3.1 Curva ROC y umbral de detección de la proteína MCP4 4.3.2 Prueba Mann Whitney 4.4 Rol de la proteína MCP4 en la Esclerosis Sistémica 4.4.1 Características sociodemográficas 4.4.2 Comorbilidades asociadas, poliautoinmunidad y tratamiento 5. DISCUSIÓN 6. CONCLUSIONES 7. REFERENCIAS BIBLIOGRAFICASPregradoBacteriólogo(a) y Laboratorista Clínico72p.application/pdfspaUniversidad Colegio Mayor de CundinamarcaFacultad de Ciencias de la SaludBacteriología y Laboratorio ClínicoDerechos Reservados - Universidad Colegio Mayor de Cundinamarca, 2024https://creativecommons.org/licenses/by-nc-nd/4.0/info:eu-repo/semantics/closedAccessAtribución-NoComercial-SinDerivadas 4.0 Internacional (CC BY-NC-ND 4.0)http://purl.org/coar/access_right/c_14cbMCP4 como biomarcador de diagnóstico en Esclerosis SistémicaTrabajo de grado - Pregradohttp://purl.org/coar/resource_type/c_7a1fhttp://purl.org/coar/version/c_970fb48d4fbd8a85Textinfo:eu-repo/semantics/bachelorThesishttps://purl.org/redcol/resource_type/TPinfo:eu-repo/semantics/publishedVersionJorge Mario Palmezano-Díaz, Claudia Lucía Figueroa-Pineda, Reynaldo Mauricio Rodríguez-Amaya, Lisette Katherine Plazas-Rey. Prevalence and characterization of autoimmune diseases in patients older than 13 years in a hospital of Colombia. Medicina interna de Mexico. 2018;34(4).Abul K. Abbas AHLSP. Mecanismos de autoinmunidad . In: Inmunología celular y molecular. 9th ed. 2018.Nicole JA, Iván GA. Inmunopatogenia de las enfermedades autoinmunes. Revista Médica Clínica Las Condes. 2012 Jul;23(4):464–72.Lerner A, Jeremias P, Matthias T. The World Incidence and Prevalence of Autoimmune Diseases is Increasing. International Journal of Celiac Disease. 2016 May 5;3(4):151–5.Londoño J, Peláez Ballestas I, Cuervo F, Angarita I, Giraldo R, Rueda JC, et al. Prevalencia de la enfermedad reumática en Colombia, según estrategia COPCORD- Asociación Colombiana de Reumatología. Estudio de prevalencia de enfermedad reumática en población colombiana mayor de 18 años. Revista Colombiana de Reumatología. 2018 Oct;25(4):245–56.Rosendahl A, Schönborn K, Krieg T. Pathophysiology of systemic sclerosis (scleroderma). Kaohsiung J Med Sci. 2022 Mar 2;38(3):187–95.J. J. Alegre Sancho EBCICVNFLJICJARI. Esclerosis sistemica . In: Enfermedades reumáticas: Actualización SVR. Valencia: Hospital Universitario Dr. Peset;Jerjen R, Nikpour M, Krieg T, Denton CP, Saracino AM. Systemic sclerosis in adults. Part I: Clinical features and pathogenesis. J Am Acad Dermatol. 2022 Nov;87(5):937– 54.Bobeica C, Niculet E, Halip A, Gheuca-Solovastru L, Draganescu M, Popescu I, et al. Predictive value of immunological markers in systemic sclerosis. Exp Ther Med. 2021 Jul 14;22(3):994.Furue M, Mitoma C, Mitoma H, Tsuji G, Chiba T, Nakahara T, et al. Pathogenesis of systemic sclerosis—current concept and emerging treatments. Immunol Res. 2017 Aug 9;65(4):790–7.Sandra S. Arango V. Biomarkers for the evaluation of human health risks. Revista Facultad Nacional de Salud Pública. 2012;Coffey C, Radwan Y, Sandhu A, Crowson CS, Bauer P, Matteson E, et al. POS0838 EPIDEMIOLOGY AND TRENDS IN SURVIVAL OF SYSTEMIC SCLEROSIS IN OLMSTED COUNTY: A POPULATION-BASED STUDY (1980-2018). Ann Rheum Dis. 2021 Jun 19;80(Suppl 1):673.1-673.MANNO RL, WIGLEY FM, GELBER AC, HUMMERS LK. Late-age Onset Systemic Sclerosis. J Rheumatol. 2011 Jul;38(7):1317–25.Bergamasco A, Hartmann N, Wallace L, Verpillat P. <p>Epidemiology of systemic sclerosis and systemic sclerosis-associated interstitial lung disease</p>. Clin Epidemiol. 2019 Apr;Volume 11:257–73.The Lancet. Reducing the cost of rare disease drugs. The Lancet. 2015 Feb;385(9970):746.MinSalud. Resolución 023 de 2023- Enfermedades huerfanas. Ministerio de Salud y Protección Social, 023 Colombia; Jan 4, 2023.Ministerio de salud. Enfermedades huerfanas. 2023 Jan.Castro S V, Jimenez SA. Biomarkers in systemic sclerosis. Biomark Med. 2010 Feb;4(1):133–47.Arron JR. Biomarkers in systemic sclerosis: mechanistic insights into pathogenesis and treatment. Curr Opin Rheumatol. 2021 Nov;33(6):480–5.Hasegawa M, Sato S, Echigo T, Hamaguchi Y, Yasui M, Takehara K. Up regulated expression of fractalkine/CX3CL1 and CX 3CR1 in patients with systemic sclerosis. Ann Rheum Dis. 2005;64(1).O’Brien JC, Rainwater YB, Malviya N, Cyrus N, Auer-Hackenberg L, Hynan LS, et al. Transcriptional and Cytokine Profiles Identify CXCL9 as a Biomarker of Disease Activity in Morphea. Journal of Investigative Dermatology. 2017 Aug;137(8):1663– 70.Li L, Dai F, Wang L, Sun Y, Mei L, Ran Y, et al. CCL13 and human diseases. Front Immunol. 2023 Apr 19;14.LAMKHIOUED B, GARCIA-ZEPEDA EA, ABI-YOUNES S, NAKAMURA H, JEDRZKIEWICZ S, WAGNER L, et al. Monocyte Chemoattractant Protein (MCP)-4 Expression in the Airways of Patients with Asthma. Am J Respir Crit Care Med. 2000 Aug 1;162(2):723–32.Iwamoto T, Okamoto H, Iikuni N, Takeuchi M, Toyama Y, Tomatsu T, et al. Monocyte chemoattractant protein-4 (MCP-4)/CCL13 is highly expressed in cartilage from patients with rheumatoid arthritis. Rheumatology (Oxford). 2006 Apr;45(4):421– 4.Truchetet ME, Brembilla NC, Chizzolini C. Current Concepts on the Pathogenesis of Systemic Sclerosis. Clin Rev Allergy Immunol. 2021 Sep 6;64(3):262–83.Unidad de enfermedades autoinmunes: experiencia de un centro. Revista Uruguaya de Medicina Interna. 2020 Oct 10;05(03).Arnett FC. HLA and Autoimmunity in Scleroderma (Systemic Sclerosis). Int Rev Immunol. 1995 Jan 10;12(2–4):107–28.Diot E. Systemic sclerosis and occupational risk factors: a case-control study. Occup Environ Med. 2002 Aug 1;59(8):545–9.Garabrant DH. Scleroderma and Solvent Exposure among Women. Am J Epidemiol. 2003 Mar 15;157(6):493–500.Olink [Internet]. 2023. Proximity Extension Assay (PEA) technology.Yanaba K, Yoshizaki A, Muroi E, Hara T, Ogawa F, Shimizu K, et al. CCL13 is a promising diagnostic marker for systemic sclerosis. British Journal of Dermatology. 2010;162(2).Gabrielli A, Avvedimento E V, Krieg T. Scleroderma. N Engl J Med. 2009 May 7;360(19):1989–2003.Mónica Ferrer Gracia, Laura María Cuadra Giménez, María de las Mercedes Díez Angulo, Alaitz Saiz Ferrer, María Sanmartín Xifré, Raúl Fernández Peñarroya. Esclerodermia: aspectos conceptuales, epidemiológicos, etiopatogénicos y clínicos. Artículo monográfico. Revista sanitaria de Investigación. 2021;Rubio-Rivas M, Royo C, Simeón CP, Corbella X, Fonollosa V. Mortality and survival in systemic sclerosis: Systematic review and meta-analysis. Semin Arthritis Rheum. 2014 Oct;44(2):208–19.Fernández-Ávila DG, Bernal-Macías S, Gutiérrez JM, Rincón DN, Rosselli D. Prevalence of systemic sclerosis in Colombia: Data from the National Health Registry 2012–2016. J Scleroderma Relat Disord. 2020 Jun 19;5(2):137–42.Varga J, Trojanowska M, Kuwana M. Pathogenesis of systemic sclerosis: recent insights of molecular and cellular mechanisms and therapeutic opportunities. J Scleroderma Relat Disord. 2017 Sep 19;2(3):137–52.Ruiz Gutiérrez L, Pérez Gómez A. Protocolo diagnóstico del fenómeno de Raynaud. Medicine - Programa de Formación Médica Continuada Acreditado. 2013;11(32):1997–2000.Choi E, Henkin S. Raynaud’s phenomenon and related vasospastic disorders. Vascular Medicine. 2021 Feb 10;26(1):56–70.Thulesius O. Methods for the evaluation of peripheral vascular function in the upper extremities. Acta Chir Scand Suppl. 1976;465:53–4.Olga Lidia Vera Lastra. Esclerosis sistémica. Medicina Interna de México. 2006 May;22(3).Shapiro SC, Wigley FM. Treating Raynaud phenomenon: Beyond staying warm. Cleve Clin J Med. 2017 Oct;84(10):797–804.Consejo general de colegios oficiales de farmaceuticos. ESCLEROSIS SISTÉMICA (ESCLERODERMIA). Punto farmacologico . 2017;Khanna D, Furst DE, Clements PJ, Allanore Y, Baron M, Czirjak L, et al. Standardization of the modified Rodnan skin score for use in clinical trials of systemic sclerosis. J Scleroderma Relat Disord. 2017;2(1):11–8.Aspe Unanue L, González Hermosa MR, Gardeazabal García J. Esclerodermia (esclerosis sistémica). Piel. 2010 May;25(5):252–66.Herrick AL, Assassi S, Denton CP. Skin involvement in early diffuse cutaneous systemic sclerosis: an unmet clinical need. Nat Rev Rheumatol. 2022 May 15;18(5):276–85.Jiménez-Gallo D, Ossorio-García L, Linares-Barrios M. Calcinosis cutis y calcifilaxis. Actas Dermosifiliogr. 2015 Dec;106(10):785–94.Wilkinson JM, Halland M. Esophageal Motility Disorders. Am Fam Physician. 2020 Sep 1;102(5):291–6.Centros para el control y prevencion de enfermedades. Información sobre la telangiectasia hemorrágica hereditaria. 2013.Janosik DL, Osborn TG, Moore TL, Shah DG, Kenney RG, Zuckner J. Heart disease in systemic sclerosis. Semin Arthritis Rheum. 1989 Dec;19(3):191–200.Steen VD. Kidney involvement in systemic sclerosis. Presse Med. 2014 Oct;43(10):e305–14.Lock G, Holstege A, Lang B, Schölmerich J. Gastrointestinal manifestations of progressive systemic sclerosis. Am J Gastroenterol. 1997 May;92(5):763–71.Azarbani N, Javadzadeh A, Mohseni I, Jalali A, Andalib E, Poormoghim H. Association of Musculoskeletal and Radiological Features with Clinical and Serological Findings in Systemic Sclerosis: A Single-Centre Registry Study. Mediterr J Rheumatol. 2020;31(3):341.Paloma García de la Peña Lefebvre. Esclerosis sistémica. Sociedad Española de Reumatología Pediátrica . 2020;173–85.Sobolewski P, Maślińska M, Wieczorek M, Łagun Z, Malewska A, Roszkiewicz M, et al. Systemic sclerosis – multidisciplinary disease: clinical features and treatment. Rheumatology. 2019 Sep 24;57(4):221–33.De Pieri A, Korman BD, Jüngel A, Wuertz‐Kozak K. Engineering Advanced In Vitro Models of Systemic Sclerosis for Drug Discovery and Development. Adv Biol. 2021 Apr 15;5(4).Marie I, Gehanno JF. Environmental risk factors of systemic sclerosis. Semin Immunopathol. 2015 Sep 4;37(5):463–73.Luo Y, Wang Y, Wang Q, Xiao R, Lu Q. Systemic sclerosis: Genetics and epigenetics. J Autoimmun. 2013 Mar;41:161–7.Ouchene L, Muntyanu A, Lavoué J, Baron M, Litvinov I V., Netchiporouk E. Toward Understanding of Environmental Risk Factors in Systemic Sclerosis. J Cutan Med Surg. 2021 Mar 28;25(2):188–204.DENTON CP, BICKERSTAFF MCM, SHIWEN X, CARULLI MT, HASKARD DO, DUBOIS RM, et al. SERIAL CIRCULATING ADHESION MOLECULE LEVELS REFLECT DISEASE SEVERITY IN SYSTEMIC SCLEROSIS. Rheumatology. 1995;34(11):1048–54.Bagabir RA, Syed F, Rautemaa R, McGrouther DA, Paus R, Bayat A. Upregulation of Toll-Like Receptors (TLRs) 6, 7, and 8 in Keloid Scars. Journal of Investigative Dermatology. 2011 Oct;131(10):2128–30.Bhattacharyya S, Varga J. Emerging Roles of Innate Immune Signaling and Toll-Like Receptors in Fibrosis and Systemic Sclerosis. Curr Rheumatol Rep. 2015 Jan 22;17(1):2.Tan FK, Zhou X, Mayes MD, Gourh P, Guo X, Marcum C, et al. Signatures of differentially regulated interferon gene expression and vasculotrophism in the peripheral blood cells of systemic sclerosis patients. Rheumatology. 2006 Jun 1;45(6):694–702.Assassi S, Mayes MD, Arnett FC, Gourh P, Agarwal SK, McNearney TA, et al. Systemic sclerosis and lupus: Points in an interferon-mediated continuum. Arthritis Rheum. 2010 Feb;62(2):589–98.Saigusa R, Asano Y, Taniguchi T, Yamashita T, Ichimura Y, Takahashi T, et al. Multifaceted contribution of the TLR4-activated IRF5 transcription factor in systemic sclerosis. Proceedings of the National Academy of Sciences. 2015 Dec 8;112(49):15136–41.Bossini-Castillo L, Martín JE, Díaz-Gallo LM, Rueda B, Martín J. Genética de la esclerodermia. Reumatol Clin. 2010 Sep;6:12–5.Brkic Z, van Bon L, Cossu M, van Helden-Meeuwsen CG, Vonk MC, Knaapen H, et al. The interferon type I signature is present in systemic sclerosis before overt fibrosis and might contribute to its pathogenesis through high BAFF gene expression and high collagen synthesis. Ann Rheum Dis. 2016 Aug;75(8):1567–73.Stifano G, Christmann RB. Macrophage Involvement in Systemic Sclerosis: Do We Need More Evidence? Curr Rheumatol Rep. 2016 Jan 23;18(1):2.Zhang Y, McCormick LL, Desai SR, Wu C, Gilliam AC. Murine Sclerodermatous Graft-Versus-Host Disease, a Model for Human Scleroderma: Cutaneous Cytokines, Chemokines, and Immune Cell Activation. The Journal of Immunology. 2002 Mar 15;168(6):3088–98.Lescoat A, Lecureur V, Roussel M, Sunnaram BL, Ballerie A, Coiffier G, et al. CD16- positive circulating monocytes and fibrotic manifestations of systemic sclerosis. Clin Rheumatol. 2017 Jul 14;36(7):1649–54.Yamamoto T, Eckes B, Krieg T. High expression and autoinduction of monocyte chemoattractant protein-1 in scleroderma fibroblasts. Eur J Immunol. 2001 Oct;31(10):2936–41.Chizzolini C, Boin F. The role of the acquired immune response in systemic sclerosis. Semin Immunopathol. 2015 Sep 8;37(5):519–28.O’Reilly S, Hugle T, van Laar JM. T cells in systemic sclerosis: a reappraisal. Rheumatology. 2012 Sep 1;51(9):1540–9.Brown M, O’Reilly S. The immunopathogenesis of fibrosis in systemic sclerosis. Clin Exp Immunol. 2019 Feb 18;195(3):310–21.Kalogerou A. Early T cell activation in the skin from patients with systemic sclerosis. Ann Rheum Dis. 2005 Aug 1;64(8):1233–5.Thoreau B, Chaigne B, Renaud A, Mouthon L. Pathophysiology of systemic sclerosis. Presse Med. 2021 Apr;50(1):104087.Hua-Huy T, Dinh-Xuan AT. Cellular and molecular mechanisms in the pathophysiology of systemic sclerosis. Pathologie Biologie. 2015 Apr;63(2):61–8.Asano Y. The Pathogenesis of Systemic Sclerosis: An Understanding Based on a Common Pathologic Cascade across Multiple Organs and Additional Organ-Specific Pathologies. J Clin Med. 2020 Aug 19;9(9):2687.HASEGAWA M. B lymphocytes: Shedding new light on the pathogenesis of systemic sclerosis. J Dermatol. 2010 Jan 24;37(1):3–10.Yoshizaki A. Pathogenic roles of B lymphocytes in systemic sclerosis. Immunol Lett. 2018 Mar;195:76–82.Roberts AB, Sporn MB. Physiological Actions and Clinical Applications of Transforming Growth Factor-β (TGF-β). Growth Factors. 1993 Jan 11;8(1):1–9.Boltjes A, van Wijk F. Human Dendritic Cell Functional Specialization in Steady- State and Inflammation. Front Immunol. 2014 Apr 1;5.Audiger C, Rahman MJ, Yun TJ, Tarbell K V., Lesage S. The Importance of Dendritic Cells in Maintaining Immune Tolerance. The Journal of Immunology. 2017 Mar 15;198(6):2223–31.Granot T, Senda T, Carpenter DJ, Matsuoka N, Weiner J, Gordon CL, et al. Dendritic Cells Display Subset and Tissue-Specific Maturation Dynamics over Human Life. Immunity. 2017 Mar;46(3):504–15.Carvalheiro T, Zimmermann M, Radstake TRDJ, Marut W. Novel insights into dendritic cells in the pathogenesis of systemic sclerosis. Clin Exp Immunol. 2020 Jun 11;201(1):25–33.Shima Y. Cytokines Involved in the Pathogenesis of SSc and Problems in the Development of Anti-Cytokine Therapy. Cells. 2021 May 4;10(5):1104.Kikuchi K, Hartl CW, Smith EA, LeRoy EC, Trojanowska M. Direct demonstration of transcriptional activation of collagen gene expression in systemic sclerosis fibroblasts: Insensitivity to TGFβ1 stimulation. Biochem Biophys Res Commun. 1992 Aug;187(1):45–50.Juhl P, Bondesen S, Hawkins CL, Karsdal MA, Bay-Jensen AC, Davies MJ, et al. Dermal fibroblasts have different extracellular matrix profiles induced by TGF-β, PDGF and IL-6 in a model for skin fibrosis. Sci Rep. 2020 Oct 14;10(1):17300.Igarashi A, Nashiro K, Kikuchi K, Sato S, Ihn H, Grotendorst GR, et al. Significant Correlation Between Connective Tissue Growth Factor Gene Expression and Skin Sclerosis in Tissue Sections from Patients with Systemic Sclerosis. Journal of Investigative Dermatology. 1995 Aug;105(2):280–4.Aspe Unanue L, González Hermosa MR, Gardeazabal García J. Esclerodermia (esclerosis sistémica). Piel. 2010 May;25(5):252–66.Umehara H, Kumagai S, Ishida H, Suginoshita T, Maeda M, Imura H. Enhanced production of interleukin‐2 in patients with progressive systemic sclerosis. hyperactivity of cd4‐positive t cells? Arthritis Rheum. 1988 Mar 29;31(3):401–7.Maria ATJ, Bourgier C, Martinaud C, Borie R, Rozier P, Rivière S, et al. De la fibrogenèse à la fibrose : mécanismes physiopathologiques et présentations cliniques. Rev Med Interne. 2020 May;41(5):325–9.Pannu J, Trojanowska M. Recent advances in fibroblast signaling and biology in scleroderma. Curr Opin Rheumatol. 2004 Nov;16(6):739–45.Adriana Acosta Gómez. El fibroblasto: su origen, estructura, funciones y heterogeneidad. Universitas Odonto. 2006;25(57):26–33.Ornitz DM, Itoh N. The Fibroblast Growth Factor signaling pathway. WIREs Developmental Biology. 2015 May 13;4(3):215–66.Denton CP, Black CM, Abraham DJ. Mechanisms and consequences of fibrosis in systemic sclerosis. Nat Clin Pract Rheumatol. 2006 Mar;2(3):134–44.Damoiseaux J, Potjewijd J, Smeets RL, Bonroy C. Autoantibodies in the disease criteria for systemic sclerosis: The need for specification for optimal application. J Transl Autoimmun. 2022;5:100141.Chen XH, Huang S, Kerr D. Biomarkers in clinical medicine. IARC Sci Publ. 2011;(163):303–22.van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A, et al. 2013 Classification Criteria for Systemic Sclerosis: An American College of Rheumatology/European League Against Rheumatism Collaborative Initiative. Arthritis Rheum. 2013 Nov;65(11):2737–47.Anna Bazsó, Emese Kiss. The Role of Biomarkers in the Pathogenesis, Clinical Manifestations, and Therapeutic Approach in Systemic Sclerosis. Preprints (Basel). 2023 Aug 8;Domsic RT, Medsger TA. Autoantibodies and Their Role in Scleroderma Clinical Care. Curr Treatm Opt Rheumatol. 2016 Sep 14;2(3):239–51.Cavazzana I, Vojinovic T, Airo’ P, Fredi M, Ceribelli A, Pedretti E, et al. Systemic Sclerosis-Specific Antibodies: Novel and Classical Biomarkers. Clin Rev Allergy Immunol. 2022 Jun 18;64(3):412–30.Kowal-Bielecka O, Fransen J, Avouac J, Becker M, Kulak A, Allanore Y, et al. Update of EULAR recommendations for the treatment of systemic sclerosis. Ann Rheum Dis. 2017 Aug;76(8):1327–39.Chen XH, Huang S, Kerr D. Biomarkers in clinical medicine. IARC Sci Publ. 2011;(163):303–22.Chen XH, Huang S, Kerr D. Biomarkers in clinical medicine. IARC Sci Publ. 2011;(163):303–22.Utsunomiya A, Oyama N, Hasegawa M. Potential Biomarkers in Systemic Sclerosis: A Literature Review and Update. J Clin Med. 2020 Oct 22;9(11):3388.Utsunomiya A, Oyama N, Hasegawa M. Potential Biomarkers in Systemic Sclerosis: A Literature Review and Update. J Clin Med. 2020 Oct 22;9(11):3388.Farmaki E, Chatzistamou I, Kiaris H. Human MCP Chemokine Cluster. In: Encyclopedia of Signaling Molecules. Cham: Springer International Publishing; 2018. p. 2482–9.Barinka C, Prahl A, Lubkowski J. Structure of human monocyte chemoattractant protein 4 (MCP-4/CCL13). Acta Crystallogr D Biol Crystallogr. 2008 Mar 1;64(3):273–8.Mendez-Enriquez E, García-Zepeda EA. The multiple faces of CCL13 in immunity and inflammation. Inflammopharmacology. 2013 Dec 12;21(6):397–406.Garcia-Zepeda EA, Combadiere C, Rothenberg ME, Sarafi MN, Lavigne F, Hamid Q, et al. Human monocyte chemoattractant protein (MCP)-4 is a novel CC chemokine with activities on monocytes, eosinophils, and basophils induced in allergic and nonallergic inflammation that signals through the CC chemokine receptors (CCR)-2 and -3. J Immunol. 1996 Dec 15;157(12):5613–26.Li L, Dai F, Wang L, Sun Y, Mei L, Ran Y, et al. CCL13 and human diseases. Front Immunol. 2023 Apr 19;14.Barinka C, Prahl A, Lubkowski J. Structure of human monocyte chemoattractant protein 4 (MCP-4/CCL13). Acta Crystallogr D Biol Crystallogr. 2008 Mar 1;64(3):273–8.Hein H, Schlüter C, Kulke R, Christophers E, Schröder JM, Bartels J. Genomic Organization, Sequence Analysis and Transcriptional Regulation of the Human MCP-4 Chemokine Gene (SCYA13) in Dermal Fibroblasts: A Comparison to Other Eosinophilic β-Chemokines. Biochem Biophys Res Commun. 1999 Feb;255(2):470–6.Gambichler T, Yilmaz E, Höxtermann S, Kolios A, Moritz R, Bechara FG, et al. Serum CCL13 levels in patients with systemic sclerosis and controls. British Journal of Dermatology. 2011 Jul;165(1):216–8.Petering H, Höchstetter R, Kimmig D, Smolarski R, Kapp A, Elsner J. Detection of MCP-4 in dermal fibroblasts and its activation of the respiratory burst in human eosinophils. J Immunol. 1998 Jan 15;160(2):555–8.Li L, Dai F, Wang L, Sun Y, Mei L, Ran Y, et al. CCL13 and human diseases. Front Immunol. 2023 Apr 19;14.Yanaba K, Yoshizaki A, Muroi E, Hara T, Ogawa F, Shimizu K, et al. CCL13 is a promising diagnostic marker for systemic sclerosis. British Journal of Dermatology. 2010;162(2).Polania Maria Daniela, Higuera Maria. FRECUENCIA DE POLIAUTOINMUNIDAD EN ESCLEROSIS SISTÉMICA. Universidad del Rosario . 2020 Jun;Prince HE. Biomarkers for diagnosing and monitoring autoimmune diseases. Biomarkers. 2005 Jan 20;10(sup1):44–9.Vona R, Giovannetti A, Gambardella L, Malorni W, Pietraforte D, Straface E. Oxidative stress in the pathogenesis of systemic scleroderma: An overview. J Cell Mol Med. 2018 Jul 17;22(7):3308–14.Minier T, Guiducci S, Bellando-Randone S, Bruni C, Lepri G, Czirják L, et al. Preliminary analysis of the very early diagnosis of systemic sclerosis (VEDOSS) EUSTAR multicentre study: evidence for puffy fingers as a pivotal sign for suspicion of systemic sclerosis. Ann Rheum Dis 2014;73:2087-93AutoinmunidadEsclerosis SistémicaRespuesta inmuneProteínaBiomarcadorConcentraciónFisiopatologíaDiagnosticoORIGINALMCP4 COMO BIOMARCADOR DE DIAGNOSTICO EN ESCLEROSIS SISTEMICA FINAL-JUANA MAYORGA JIMENEZ (1).pdfMCP4 COMO BIOMARCADOR DE DIAGNOSTICO EN ESCLEROSIS SISTEMICA FINAL-JUANA MAYORGA JIMENEZ (1).pdfapplication/pdf1619892https://repositorio.unicolmayor.edu.co/bitstream/unicolmayor/7033/12/MCP4%20COMO%20BIOMARCADOR%20DE%20DIAGNOSTICO%20EN%20ESCLEROSIS%20SISTEMICA%20FINAL-JUANA%20MAYORGA%20JIMENEZ%20%281%29.pdfdf4cee61891ab5e546e1d4c0964c7824MD512open accessCARTA DERECHOS DE AUTOR IP 2024.docx (24).pdfCARTA DERECHOS DE AUTOR IP 2024.docx (24).pdfapplication/pdf100954https://repositorio.unicolmayor.edu.co/bitstream/unicolmayor/7033/13/CARTA%20DERECHOS%20DE%20AUTOR%20IP%202024.docx%20%2824%29.pdff83fd50d83dd30eacd27e01cbff63b7dMD513metadata only accessFORMATO IDENTIFICACIÓN TRABAJO DE GRADO MCP4.pdfFORMATO IDENTIFICACIÓN TRABAJO DE GRADO MCP4.pdfapplication/pdf271419https://repositorio.unicolmayor.edu.co/bitstream/unicolmayor/7033/14/FORMATO%20IDENTIFICACIO%cc%81N%20TRABAJO%20DE%20GRADO%20MCP4.pdfa5ce708657c4d520aa3638c487781ffeMD514metadata only accessLICENSElicense.txtlicense.txttext/plain; charset=utf-814828https://repositorio.unicolmayor.edu.co/bitstream/unicolmayor/7033/5/license.txt2f9959eaf5b71fae44bbf9ec84150c7aMD55open accessTEXTMCP4 COMO BIOMARCADOR DE DIAGNOSTICO EN ESCLEROSIS SISTEMICA FINAL-JUANA MAYORGA JIMENEZ (1).pdf.txtMCP4 COMO BIOMARCADOR DE DIAGNOSTICO EN ESCLEROSIS SISTEMICA FINAL-JUANA MAYORGA JIMENEZ (1).pdf.txtExtracted texttext/plain126357https://repositorio.unicolmayor.edu.co/bitstream/unicolmayor/7033/6/MCP4%20COMO%20BIOMARCADOR%20DE%20DIAGNOSTICO%20EN%20ESCLEROSIS%20SISTEMICA%20FINAL-JUANA%20MAYORGA%20JIMENEZ%20%281%29.pdf.txtc7abe868c5aa95ed142fff1059dbc553MD56open accessCARTA DERECHOS DE AUTOR IP 2024.docx (24).pdf.txtCARTA DERECHOS DE AUTOR IP 2024.docx (24).pdf.txtExtracted texttext/plain1017https://repositorio.unicolmayor.edu.co/bitstream/unicolmayor/7033/8/CARTA%20DERECHOS%20DE%20AUTOR%20IP%202024.docx%20%2824%29.pdf.txt38d869c455dd226c5a8e04ec55247d27MD58metadata only accessFORMATO IDENTIFICACIÓN TRABAJO DE GRADO MCP4.pdf.txtFORMATO IDENTIFICACIÓN TRABAJO DE GRADO MCP4.pdf.txtExtracted texttext/plain2768https://repositorio.unicolmayor.edu.co/bitstream/unicolmayor/7033/10/FORMATO%20IDENTIFICACIO%cc%81N%20TRABAJO%20DE%20GRADO%20MCP4.pdf.txt208f81372697180681b2bef13526b827MD510metadata only accessTHUMBNAILMCP4 COMO BIOMARCADOR DE DIAGNOSTICO EN ESCLEROSIS SISTEMICA FINAL-JUANA MAYORGA JIMENEZ (1).pdf.jpgMCP4 COMO BIOMARCADOR DE DIAGNOSTICO EN ESCLEROSIS SISTEMICA FINAL-JUANA MAYORGA JIMENEZ (1).pdf.jpgGenerated Thumbnailimage/jpeg7122https://repositorio.unicolmayor.edu.co/bitstream/unicolmayor/7033/7/MCP4%20COMO%20BIOMARCADOR%20DE%20DIAGNOSTICO%20EN%20ESCLEROSIS%20SISTEMICA%20FINAL-JUANA%20MAYORGA%20JIMENEZ%20%281%29.pdf.jpga27e8afbd597ec8aa618a3272c1dc48dMD57open accessCARTA DERECHOS DE AUTOR IP 2024.docx (24).pdf.jpgCARTA DERECHOS DE AUTOR IP 2024.docx (24).pdf.jpgGenerated Thumbnailimage/jpeg9562https://repositorio.unicolmayor.edu.co/bitstream/unicolmayor/7033/9/CARTA%20DERECHOS%20DE%20AUTOR%20IP%202024.docx%20%2824%29.pdf.jpg1045ac1f786e56ae8268b72cc7c03086MD59metadata only accessFORMATO IDENTIFICACIÓN TRABAJO DE GRADO MCP4.pdf.jpgFORMATO IDENTIFICACIÓN TRABAJO DE GRADO MCP4.pdf.jpgGenerated Thumbnailimage/jpeg12029https://repositorio.unicolmayor.edu.co/bitstream/unicolmayor/7033/11/FORMATO%20IDENTIFICACIO%cc%81N%20TRABAJO%20DE%20GRADO%20MCP4.pdf.jpg3eadd79cc8860550531870c88635ec68MD511metadata only accessunicolmayor/7033oai:repositorio.unicolmayor.edu.co:unicolmayor/70332024-09-19 12:02:26.221An error occurred on the license name.|||https://creativecommons.org/licenses/by-nc-nd/4.0/open accessBiblioteca Digital Unicolmayorrepositorio@unicolmayor.edu.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

Publicaciones similares